{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:42:19Z","timestamp":1790628139098,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":110,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,9]]},"abstract":"<jats:p>A highly increased risk of myelodysplasia (MDS) and acute myeloid leukaemia (AML) is well established in patients previously treated for other malignancies with alkylating agents or topoisomerase II inhibitors. More recently, single cases of acute lymphoblastic leukaemia (ALL), often presenting balanced translocations involving chromosome band 11q23, have been observed. We present two such cases with t(4;11)(q21;q23), one of whom had previously received only single\u2010agent chemotherapy with 4\u2010epi\u2010doxorubicin. A review of the literature since 1992 including these two patients reveals a total of 23 cases of ALL or lymphoblastic lymphoma after chemotherapy presenting balanced translocations to 11q23. All 23 patients had previously received at least one topoisomerase II inhibitor, and in two patients 4\u2010epi\u2010doxorubicin had been administered as single\u2010agent chemotherapy for breast cancer. The latency period to development of t\u2010ALL was 24\u2003months or less in 20 out of 22 cases. The <jats:italic>MLL<\/jats:italic> gene was found to be rearranged in 14 out of 14 cases, and in three out of six cases the breakpoint was at the telomeric part of the gene, as observed in most cases of AML following therapy with topoisomerase II inhibitors. These results indicate that patients with ALL and balanced translocations to chromosome band 11q23 following chemotherapy with topoisomerase II inhibitors in the future should be included with cases of MDS or AML in calculations of risk of leukaemia.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.03000.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:37:29Z","timestamp":1047364649000},"page":"539-543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Therapy\u2010related acute lymphoblastic leukaemia with <i>MLL<\/i> rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992"],"prefix":"10.1111","volume":"114","author":[{"given":"Mette Klarskov","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debes H.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne Anker","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Pedersen\u2010Bjergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"483","article-title":"Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements","volume":"83","author":"Andersen M.K.","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695815"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401391"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.V87.5.1912.1912","article-title":"Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment\u2010related acute myeloid leukemia. Correlation with scaffold attachment regions and topoisomerase II consensus binding sites","volume":"87","author":"Broeker P.L.S.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_6_1","first-page":"2879","article-title":"Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary leukemias","volume":"57","author":"Cimino G.","year":"1997","journal-title":"Cancer Research"},{"key":"e_1_2_6_7_1","first-page":"1305","article-title":"Molecular analysis of 13 cases of MLL\/11q23 secondary acute leukemia and identification of topoisomerase II consensus\u2010binding sequences near the chromosomal breakpoint of a secondary leukemia with t(4;11)","volume":"9","author":"Domer P.H.","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.11.3250.bloodjournal85113250"},{"key":"e_1_2_6_9_1","first-page":"2326","article-title":"Sequence analysis of the breakpoint cluster region in the ALL\u20101 gene involved in acute leukemia","volume":"54","author":"Gu Y.","year":"1994","journal-title":"Cancer Research"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.156"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-911x(199607)27:1<54::aid-mpo10>3.0.co;2-5"},{"key":"e_1_2_6_12_1","first-page":"2224","article-title":"Distinct MLL gene rearrangements associated with successive acute monocytic and lymphoblastic leukemias in the same patient","volume":"8","author":"Jonveaux P.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood.V82.10.3220.3220","article-title":"HRX gene rearrangement in acute lymphoblastic leukemia after adjuvant chemotherapy of breast cancer","volume":"82","author":"Kobayashi Y.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1008"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11583"},{"key":"e_1_2_6_16_1","volume-title":"Catalog of Chromosome Aberrations in Cancer","author":"Mitelman F.","year":"1998"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04844.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199709114180"},{"key":"e_1_2_6_19_1","first-page":"256","article-title":"Therapy\u2013related myelodysplastic syndromes","volume":"33","author":"Park D.J.","year":"1996","journal-title":"Seminars in Hematology"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(92)90150-6"},{"key":"e_1_2_6_21_1","first-page":"1975","article-title":"Therapy\u2010related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohort of patients treated intensively for malignant diseases in the Copenhagen series","volume":"7","author":"Pedersen\u2010Bjergaard J.","year":"1993","journal-title":"Leukemia"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019809009515"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209053620"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01843.x"},{"key":"e_1_2_6_25_1","first-page":"535","article-title":"All patients with the t(11;16) (q23;p13.3) that involves MLL and CBP have treatment\u2010related hematologic disorders","volume":"90","author":"Rowley J.D.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401021"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401558"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00399.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80037-0"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03000.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03000.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.03000.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:44:38Z","timestamp":1697442278000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.03000.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["10.1046\/j.1365-2141.2001.03000.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03000.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}